Search results

Skip to results

Area of interest

Area of interest





Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 131 results for hepatitis

  1. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)

  2. Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (TA331)

    The guidance has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

  3. Learning disability: care and support of people growing older (QS187)

    This quality standard covers identifying, assessing and regularly reviewing the care and support needs of people with a learning disability as they grow older. People with a learning disability have many of the same age-related health and social care needs as other people, but this quality standard focuses on the specific challenges associated with their learning disability. It describes high-quality care in priority areas for improvement.

  4. Committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  5. Golimumab for the treatment of psoriatic arthritis (TA220)

    Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.

  6. Research recommendations

    and cost effectiveness of hepatitis B surface antigen (HBsAg) quantitative assays in determining treatment duration in...

  7. Daclatasvir for treating chronic hepatitis C (TA364)

    This guidance has been withdrawn because Bristol-Myers Squibb has discontinued daclatasvir (Daklinza).

  8. Cellulitis and erysipelas: antimicrobial prescribing (NG141)

    This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.

  9. Telaprevir for the treatment of genotype 1 chronic hepatitis C (TA252)

    Telaprevir no longer has a marketing authorisation in the UK so this guidance has been withdrawn.

  10. Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)

    Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.

  11. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

  12. Sorafenib for treating advanced hepatocellular carcinoma (TA474)

    Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

  13. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged

  14. The clinical and cost effectiveness of pegylated interferon alpha 2a and alpha 2b for hepatitis C (TA14)

    This guidance has been replaced by NICE technology appraisal guidance 75.

  15. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, is collected for all people treated with sofosbuvir in the NHS.

    details Comes from guidance Sofosbuvir for treating chronic hepatitis C Number TA330 Date issued February 2015 Other